Phenomic AI Inc. has announced new collaboration agreements to help advance drug discovery for stroma-rich tumors using its Sctx single-cell transcriptomics platform.

Prism Biolab Co. Ltd. has entered into a drug discovery, license and collaboration agreement with Eli Lilly & Co.

Postera Inc. has announced a multitarget collaboration with Amgen Inc. that seeks to leverage Postera’s artificial intelligence (AI) platform, Proton, an innovation in generative chemistry and synthesis-aware design, and Amgen’s drug discovery expertise, to advance up to five small-molecule programs.

Fractyl Health Inc. has expanded an academic-industry scientific partnership focused on advancing research on the role of the gut and pancreas in metabolic disease.

The Innovative Medicines Initiative’s COMBINE (COllaboration for prevention and treatment of MDR Bacterial INfEctions) project is developing a standardized in vivo pneumonia model to test small-molecule antibiotics.

Nona Biosciences, a wholly owned subsidiary of HBM Holdings Ltd., has entered into a strategic collaboration with Genequantum Healthcare (Suzhou) Co. Ltd. to advance the early discovery of next-generation bioconjugates.

Ethris GmbH and Heqet Therapeutics srl, a company spun out last year from King’s College London, have entered into a collaboration agreement to harness the potential of non-coding RNA (ncRNA) for heart tissue regeneration following acute myocardial infarction and in heart failure.

Sosei Group Corp. and Kallyope Inc. have announced the successful identification, validation and nomination of a first G protein-coupled receptor (GPCR) target to enter a therapeutic discovery program for gastrointestinal (GI) diseases. The nominated target will advance into a structure-based drug discovery program.